Compare LBRX & GOOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LBRX | GOOS |
|---|---|---|
| Founded | 2015 | 1957 |
| Country | United States | Canada |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.5M | 987.0M |
| IPO Year | N/A | 2016 |
| Metric | LBRX | GOOS |
|---|---|---|
| Price | $28.75 | $9.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $46.60 | $12.60 |
| AVG Volume (30 Days) | 134.2K | ★ 784.0K |
| Earning Date | 05-06-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.21 |
| Revenue Next Year | N/A | $5.16 |
| P/E Ratio | ★ N/A | $75.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $9.30 |
| 52 Week High | $33.47 | $15.43 |
| Indicator | LBRX | GOOS |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 38.80 |
| Support Level | $22.39 | $9.30 |
| Resistance Level | $33.47 | $10.42 |
| Average True Range (ATR) | 1.51 | 0.32 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 72.32 | 41.96 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale; Direct to Consumer (DTC), and Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia-Pacific, and Europe, the Middle East, and Africa.